Effect of mitochondrial haplogroups on ranibizumab response in neovascular age-related macular degeneration patients: a pilot study

Esteban, O. ; Ascaso, F.J. (Universidad de Zaragoza) ; Mateo, J. ; Calvo, T. ; Montoya, J. (Universidad de Zaragoza) ; Ruiz-Pesini, E. (Universidad de Zaragoza)

Resumen: Editor,
Vascular endothelial growth factor (VEGF) is necessary for the formation of new blood vessels in neovascular age-related macular degeneration (nAMD). Thus, VEGF is a target for antiangiogenic intravitreal therapy in nAMD. One of these anti-VEGF agents is ranibizumab. Besides clinical factors, certain gene variants, that have been associated with nAMD prevalence, also influence the individual’s response to ranibizumab therapy (Dedania et al. 2015). Thus, a significant association between AMD risk and mitochondrial DNA (mtDNA) genetic background (haplogroup) has been repeatedly reported (Udar et al. 2009). We hypothesized that mtDNA genotype could partially explain the individual differences in response to ranibizumab. Patients included in the study were diagnosed of nAMD and received 3 initial monthly injections of intravitreal ranibizumab (IVR) 0.5 mg in 0.05 ml followed by a flexible pro re nata period for the remaining 8 months. The decision to re-treat was based on vision loss =5 letters...

Idioma: Inglés

DOI: 10.1111/aos.13865

Año: 2018

Publicado en: ACTA OPHTHALMOLOGICA 97, 1 (2018), e133 - e134
ISSN: 1755-375X

Factor impacto JCR: 3.153 (2018)

Categ. JCR: OPHTHALMOLOGY rank: 12 / 59 = 0.203 (2018) - Q1 - T1

Factor impacto SCIMAGO: 1.51 - Ophthalmology (Q1) - Medicine (miscellaneous) (Q1)

Tipo y forma: (Versión definitiva)

Área (Departamento): Área Oftalmología (Dpto. Cirugía,Ginecol.Obstetr.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)